Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group..

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

2.
3.
4.

Concurrent radiation and weekly cisplatin for non-small-cell lung cancer--a phase I/II study.

Abratt RP, Willcox PA, Salton DG.

Cancer Chemother Pharmacol. 1992;30(6):495-7.

PMID:
1327569
5.

Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma.

Abratt RP, Willcox PA, de Groot M, Goodman HT, Jansen ER, Salton DG.

Eur J Cancer. 1991;27(1):28-30.

PMID:
1849413
6.

Solid state thermoluminescent dosimetry.

Salton DG.

Radiography. 1971 Mar;37(435):53-7. No abstract available.

PMID:
5552511

Supplemental Content

Loading ...
Support Center